

DAFTAR PUSTAKA

- Adityo S, C. Martin Rumende, Ceva,W.Pitoyo dkk. 2020. *Corona Disese 2019: Tinjauan Literatur Terkini Disese 2019: Review of Current Literatures: Jurnal Penyakit Dalam Indonesia*, Vol.7, No.1
- Alif,Muh I. 2020. *Coronavirus: Asal-usul, Penyebaran, Dampak dan Metode Pencegehan Efektif Pandemi COVID-19*: Muhammad Alif Ibadurahman, 59 halaman.
- Altman, D.G. 1991. Sample Size. In Altman, D.G., Ed., *Practical Statistics for Medical Research*, Chapman & Hall, London, 455-460.
- Chan JF-W, Kok K-H, Zhu Z, Chu H, To KK-W, Yuan S, et al. 2020 *Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan*. *Emerg Microbes Infect.*;9(1):221-36.
- De Wit E, van Doremalen N, Falzarano D, Munster VJ.2016. *SARS and MERS: recent insights into emerging coronaviruses*. *Nat Rev Microbiol.*;14(8):523-34.
- Erlina et al. 2020. *Pedoman Tatalaksana COVID-19 Edisi 2*. Perhimpunan Dokter Paru Indonesia. Jakarta
- Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. *Proc Japan Acad Ser B Phys Biol Sci*. 2017;93(7):449-463. doi:10.2183/pjab.93.027
- Gopalakrishnan,S dan Ganeshkumar,P. 2013. *Systematic Reviews and Meta-analysis: Understanding the Best Evidence in Primary Healthcare*. *J Family Med Prim Care*. Jan;2(1):9-14.doi: 10.4103/2249-4863.109934.
- Gorbalenya AE, Baker SC, Baris RS, de Groot RJ, Drosten C, Gulyaeva AA, et al. *The spescies Severe Acute Respiratory Syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2*. *Nat Microbial*. 2020; published online March 2. DOI: 10.1038/s41564-020-0695-z
- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. 2020. *Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China*. *Lancet*.;395(10223):497-506.
- Sim,J.,Wright, CC. 2005. *The Kappa Statistic in Reliability Studies: Use, Interpretation dan Sample Size Requirements*. Physical Therapy,

Vol.85, Issue 3, 1 Maret 2005. Halaman 257-268:
<https://doi.org/10.1093/ptj/85.3.257>

- Kampf G, Todt D, Pfaender S, Steinmann E. 2020. *Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents*. J Hosp Infect.;104(3):246-51.
- Li X, Geng M, Peng Y, Meng L, Lu S. 2020. *Molecular immune pathogenesis and diagnosis of COVID-19*. J Pharm Anal.; published online March 5. DOI: 10.1016/j.jpha.03.001
- Liu Y, Gayle AA, Wilder-Smith A, Rocklöv J. 2020. *The reproductive number of COVID-19 is higher compared to SARS coronavirus*. J Travel Med. ;27(2).
- NHLBI R International. 2014. *Quality assessment tool for before-after (pre-post) studies with no control group*.
- Pharmaceuticals and Medical Devices Agency.2014. *Evaluation of Avigan Tablet 200 Mg.*;
- Perry, A. & Hammond, N. 2002. *Systematic Review: The Experience of a PhD Student*. Psychology Learning and Teaching, 2(1), 32–35.
- Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, 2020. et al. *Dysregulation of immune response in patients with COVID-19 in Wuhan, China*. Clin Infect Dis; published online March 12. DOI: 10.1093/ cid/ciaa248.
- Rayyan app. 2020. <https://rayyan.qcri.org/welcome> di akses Juni 2020
- Ren L-L, Wang Y-M, Wu Z-Q, Xiang Z-C, Guo L, Xu T, et al. 2020. *Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study*. Chin Med J; published online February 11. DOI: 10.1097/CM9.0000000000000722.
- Rothan HA, Byrareddy SN. 2020. *The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak*. J Autoimmun.; published online March 3. DOI: 10.1016/j.jaut.2020.102433.
- Sandro G, dkk. 2020. *Clinical Trials on Drug Repositioning for COVID-19 Treatment*. Rev Panam Salud Publica 44: DOI:org/10/26633/RPSP.2020.40
- Siswanto, 2010. *Systematic Review sebagai Metode Penelitian untuk Mensintesis Hasil-hasil Penelitian (Sebuah Pengantar)*; Vol.13,No.4 Oktober; Bulletin of Health System Research.

LAMPIRAN

1. Tabel hasil telaah kritis artikel 1

Experimental Treatment With Favipiravir for COVID-19: Open-Label Control Study

JBI Critical Appraisal Checklist for Quasi-Experimental Studies (non-randomized experimental studies)

Reviewer : DA,SS

Author : Qingxian Cai, *et al*

Year : 2020

		YES	NO	UNCLEAR	NA
NO	Question				
1	Is it clear in the study what is the 'cause' and what is the 'effect' (i.e. there is no confusion about which variable comes first)?	√			
2	Were the participants included in any comparisons similar?	√			
3	Were the participants included in any comparisons receiving similar treatment/care, other than the exposure or intervention of interest?	√			
4	Was there a control group?	√			
5	Were there multiple measurements of the outcome both pre and post the intervention/exposure?	√			
6	Was follow up complete and if not, were differences between groups in terms of their follow up adequately described and analyzed?		√		
7	Were the outcomes of participants included in any comparisons measured in the same way?	√			
8	Were outcomes measured in a reliable way?	√			
9	Was appropriate statistical analysis used?	√			

2. Tabel hasil telaah kritis artikel 2

Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial

JBI Critical Appraisal Checklist for Randomized Controlled Trials

Reviewer : DA,SS

Author : Chang chen,*et al*

Year : 2020

		YES	NO	UNCLEAR	NA
NO					
1	Was true randomization used for assignment of participants to treatment groups?	√			
2	Was allocation to treatment groups concealed?		√		
3	Were treatment groups similar at the baseline?	√			
4	Were participants blind to treatment assignment?		√		
5	Were those delivering treatment blind to treatment assignment?		√		
6	Were outcomes assessors blind to treatment assignment?		√		
7	Were treatment groups treated identically other than the intervention of interest?	√			
8	Was follow up complete and if not, were differences between groups in terms of their follow up adequately described and analyzed?		√		
9	Were participants analyzed in the groups to which they were randomized?	√			
10	Were outcomes measured in the same way for treatment groups?	√			
11	Were outcomes measured in a reliable way?	√			
12	Was appropriate statistical analysis used?	√			
13	Was the trial design appropriate, and any deviations from the standard RCT design (individual randomization, parallel groups) accounted for in the conduct and analysis of the trial?	√			

3. Tabel hasil telaah kritis artikel 3

Clinical Course of a Critically ill Patient with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

JBI Critical Appraisal Checklist for Case Reports

Reviewer : DA, FN

Author : Nozomi takahashi, *et al*

Year : 2020

		YES	NO	UNCLEAR	NA
NO					
1	Were patient's demographic characteristics clearly described?	√			
2	Was the patient's history clearly described and presented as a timeline?	√			
3	Was the current clinical condition of the patient on presentation clearly described?		√		
4	Were diagnostic tests or assessment methods and the results clearly described?	√			
5	Was the intervention(s) or treatment procedure(s) clearly described?			√	
6	Was the post-intervention clinical condition clearly described?			√	
7	Were adverse events (harms) or unanticipated events identified and described?		√		
8	Does the case report provide takeaway lessons?	√			

4. Tabel hasil telaah kritis artikel 4

Neuroleptic Malignant Syndrome in Patient with COVID-19

JBI Critical Appraisal Checklist for Case Reports

Reviewer : DA, FN

Author : Mitsuhiro soh, *et al*

Year : 2020

		YES	NO	UNCLEAR	NA
NO					
1	Were patient's demographic characteristics clearly described?		√		
2	Was the patient's history clearly described and presented as a timeline?	√			
3	Was the current clinical condition of the patient on presentation clearly described?	√			
4	Were diagnostic tests or assessment methods and the results clearly described?		√		
5	Was the intervention(s) or treatment procedure(s) clearly described?		√		
6	Was the post-intervention clinical condition clearly described?			√	
7	Were adverse events (harms) or unanticipated events identified and described?			√	
8	Does the case report provide takeaway lessons?	√			

5. Perhitungan nilai persetujuan tinjauan sistematis

		Pengamat 1/ reviewer 1		
		<i>Ya</i>	<i>Tidak</i>	Jumlah
Pengamat 2/ reviewer 2	<i>Ya</i>	A	B	a + b
	<i>Tidak</i>	C	D	c + d
	Jumlah	a + c	b + d	a + b + c + d = n

Ket:

$$\text{Persetujuan} = (a + d)/n \times 100\%$$

$$\text{Cohen's Kappa} = (Po - Pe) / (1 - Pe)$$

$$Po = (a + d)/n$$

$$Pe = [(a + c)(a + b)/n + (b + d)(c + d)/n] / n$$

Kategori nilai *Cohen's Kappa* (Altman, 1991):

$$0.00 \leq k \leq 0.20 = \text{Rendah}$$

$$0.21 \leq k \leq 0.40 = \text{Lumayan}$$

$$0.41 \leq k \leq 0.60 = \text{Cukup}$$

$$0.61 \leq k \leq 0.80 = \text{Baik}$$

$$0.81 \leq k \leq 1.00 = \text{Sangat baik}$$

a. Skrining Tahap I (TIAB screening)

		Pengamat 1/ reviewer 1		
		<i>Include</i>	<i>Exclude</i>	Jumlah
Pengamat 2/ reviewer 2	<i>Include</i>	26	5	31
	<i>Exclude</i>	5	121/124	126/129
	Jumlah	31	126/129	157/160

$$\begin{aligned}
 \text{Persetujuan} &= (a + d)/n \times 100\% \\
 &= (26+124)/160 \times 100\% \\
 &= 0.937 \text{ (0.937\%)}
 \end{aligned}$$

$$\begin{aligned}
 \text{Cohen's Kappa} &= (Po - Pe)/(1 - Pe) \\
 &= (0.936 - 0.683)/(1 - 0.683) \\
 &= 0.798 \text{ (Baik)}
 \end{aligned}$$

$$\begin{aligned}
 Po &= (a + d)/n \\
 &= (26+121)/157 = 0.936
 \end{aligned}$$

$$\begin{aligned}
 Pe &= [(a + c)(a + b)/n + (b + d)(c + d)/n]/n \\
 &= [(31)(31)/157 + (126)(126)/157]/157 \\
 &= 6,12 + 101,12/157 \\
 &= 0.683
 \end{aligned}$$

b. Skrining Tahap II (Full Text Screening)

		Pengamat 1/ reviewer 1		
		<i>Include</i>	<i>Exclude</i>	Jumlah
Pengamat 2/ reviewer 2	<i>Include</i>	4	0	4
	<i>Exclude</i>	0	22	22
	Jumlah	4	22	26

$$\begin{aligned}
 \text{Persetujuan} &= (a + d)/n \times 100\% \\
 &= (4+22)/26 \times 100\% \\
 &= 1 (100\%)
 \end{aligned}$$

$$\begin{aligned}
 \text{Cohen's Kappa} &= (Po-Pe)/(1-Pe) \\
 &= (1-0.739)/(1-0.739) \\
 &= 1,00 \text{ (Sangat baik)}
 \end{aligned}$$

$$\begin{aligned}
 Po &= (a + d)/n \\
 &= (4+22)/26= 1
 \end{aligned}$$

$$\begin{aligned}
 Pe &= [(a + c)(a + b)/n + (b + d)(c + d)/n]/n \\
 &= [(4)(4)/26 + (22)(22)/26]/26 \\
 &= 0.615 + 18,615/26 \\
 &= 0.739
 \end{aligned}$$